Secondary Logo

Journal Logo

AAPA Members can view Full text articles for FREE. Not a Member? Join today!

Institutional members access full text with Ovid®

Immunotherapy for non-small cell lung cancer

Vafadar, Sam MSPAS, PA-C

Journal of the American Academy of PAs: September 2019 - Volume 32 - Issue 9 - p 37–42
doi: 10.1097/01.JAA.0000569792.99069.e6
Review Article
Buy

ABSTRACT Immunotherapy is a new genre of treatment for patients with advanced cancer. Initially approved for use in metastatic melanoma, immunotherapy has found a significant place in treating non-small cell lung cancer (NSCLC). Clinical trials using several combinations of immunotherapy are underway to help to determine the best treatment for specific patient groups. This article reviews approved uses of immunotherapy for NSCLC, immune-related toxicities, and explores the future direction of this treatment.

Sam Vafadar practices thoracic oncology at Moffitt Cancer Center in Tampa, Fla. The author has disclosed no potential conflicts of interest, financial or otherwise.

Copyright © 2019 American Academy of Physician Assistants
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website